MURRAY HILL, N.J.--(BUSINESS WIRE)-- C. R. Bard, Inc. (NYS: BCR) today announced that it has entered into a definitive agreement to acquire privately-held Neomend, Inc., a leading developer and ...
Renowned medical devices maker CR Bard (BCR) recently announced a definitive agreement to purchase leading thoracic sealing company Neomend Inc. for $140 million in cash and will pay contingent ...
C. R. Bard announced that it has entered into a definitive agreement to acquire privately-held Neomend, a leading developer and supplier of sprayable surgical sealants and anti-adhesion products for a ...
C.R. Bard ($BCR) has agreed to pay $140 million up-front for Neomend, a California maker of products to seal air leaks in the lungs after surgery. The deal is ...
C.R. Bard, the Murray Hill, N.J., publicly traded medical device company, has acquired Neomend in a $140 million deal. Neomend, Irvine, Calif., which develops sprayable surgical sealants and ...
Neomend, Inc., an innovator in sealant and adhesion-prevention products for the surgical marketplace, announced it has received the European Union CE Mark for the company's ProGEL® PLATINUM Surgical ...
Novozymes Biopharma, has announced that its recombinant human albumin, albucult®, is being used by Neomend in its ProGEL® PLATINUM surgical sealant. This product will be commercially available in ...
Renowned medical devices maker CR Bard (BCR) recently announced a definitive agreement to purchase leading thoracic sealing company Neomend Inc. for $140 million in cash and will pay contingent ...
Renowned medical devices maker CR Bard ( BCR) recently announced a definitive agreement to purchase leading thoracic sealing company Neomend Inc. for $140 million in cash and will pay contingent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results